Israel Englander Tango Therapeutics, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.66 - $10.15 $27,832 - $42,416	-4,179 Reduced 21.89%	14,911 $127,000
Q1 2024 May 15, 2024	SELL	$7.51 - $12.88 $2.07 Million - $3.55 Million	-275,468 Reduced 93.52%	19,090 $151,000
Q4 2023 Feb 14, 2024	SELL	$6.52 - $12.01 $97,891 - $180,318	-15,014 Reduced 4.85%	294,558 $2.92 Million
Q2 2023 Aug 14, 2023	BUY	$2.67 - $4.7 $297,462 - $523,622	111,409 Added 56.22%	309,572 $1.03 Million
Q1 2023 May 15, 2023	BUY	$3.76 - $8.06 $635,244 - $1.36 Million	168,948 Added 578.29%	198,163 $783,000
Q4 2022 Feb 14, 2023	SELL	$3.41 - $8.29 $601,155 - $1.46 Million	-176,292 Reduced 85.78%	29,215 $212,000
Q3 2022 Nov 14, 2022	BUY	$3.25 - $5.46 $240,353 - $403,794	73,955 Added 56.22%	205,507 $744,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $359M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.